Top

Published in:

01-05-2018 | ORIGINAL ARTICLE

Is parathyroidectomy safe and effective in patients with normocalcemic primary hyperparathyroidism?

Authors: Emanuela Traini, Rocco Bellantone, Serena Elisa Tempera, Salvatore Russo, Carmela De Crea, Celestino Pio Lombardi, Marco Raffaelli

Published in: Langenbeck's Archives of Surgery | Issue 3/2018

Abstract

Purpose

Indications and advantages of parathyroidectomy in patients with normocalcemic primary hyperparathyroidism (NHPT) are still matter of debate. We aimed to compare clinical presentation and surgical outcome between normocalcemic and hypercalcemic forms in a consecutive series of patients who underwent parathyroidectomy for primary hyperparathyroidism.

Methods

Data of 731 consecutive patients were reviewed and retrospectively compared according to normocalcemic (group A) and hypercalcemic (group B) phenotypes.

Results

No significant differences were found between the two groups concerning demographics and symptomatic onset. Mean preoperative PTH levels were significantly higher in group B (252.0 ± 320.7 pg/ml vs 151.7 ± 112.0; p < 0.001). Mean PTH levels in first postoperative day were significantly lower in group B (30.9 ± 26.2 vs 22.7 ± 20.7; p < 0.001). No significant difference in overall accuracy of preoperative imaging studies was found. Significantly more patients in group A underwent bilateral explorations (83 vs 255; p < 0.05). The rate of multigland disease was significantly higher in group A (13.0 vs 6.8%; p < 0.05). At a mean follow-up period of 72.9 ± 46.8 months, all but three patients, among the 96 of group A who completed follow-up evaluation, were biochemically cured. The remaining patients had persistent high PTH values. Among NHPT patients who had target organ disease before parathyroidectomy, improvement in bone density and in kidney stones was observed in 41.7 and 40.0%, and stability in 50.0 and 60.0% respectively.

Conclusion

In normocalcemic patients, parathyroidectomy is as safe and effective as in hypercalcemic patients. In the presence of symptoms and/or target organ disease, parathyroidectomy may have a positive effect on the outcome of NHPT patients.

Monchik JM (1995) Normocalcemic hyperparathyroidism. Surgery 118(6):917–923. https://doi.org/10.1016/S0039-6060(05)80094-7 CrossRefPubMed

Siperstein AE, Shen W, Chan AK, Duh QY, Clark OH (1992) Normocalcemic hyperparathyroidism biochemical and symptom profiles before and after surgery. Arch Surg 127(10):1157–1156 discussion 1161-1153 CrossRefPubMed

Lundgren E, Rastad J, Thrufjell E, Akerstrom G, Ljunghall S (1997) Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 121(3):287–294. https://doi.org/10.1016/S0039-6060(97)90357-3 CrossRefPubMed

Cusano NE, Silverberg SJ, Bilezikian JP (2013) Normocalcemic primary hyperparathyroidism. J Clin Densitom 16(1):33–39. https://doi.org/10.1016/j.jocd.2012.12.001 CrossRefPubMedPubMedCentral

Kontogeorgos G, Trimpou P, Laine CM, Olerod G, Lindahl A, Landin-Wilhelmsen K (2015) Normocalcaemic, vitamin D-sufficient hyperparathyroidism - high prevalence and low morbidity in the general population: a long-term follow-up study, the WHO MONICA project, Gothenburg, Sweden. Clin Endocrinol 83(2):277–284. https://doi.org/10.1111/cen.12819 CrossRef

Berger C, Almohareb O, Langsetmo L, Hanley DA, Kovacs CS, Josse RG, Adachi JD, Prior JC, Towheed T, Davison KS, Kaiser SM, Brown JP, Goltzman D (2015) Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers. Clin Endocrinol 82(3):359–368. https://doi.org/10.1111/cen.12569 CrossRef

Bilezikian JP, Khan AA, Potts JT Jr (2009) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 94(2):335–339. https://doi.org/10.1210/jc.2008-1763 CrossRefPubMedPubMedCentral

Wilhelm SM, Wang TS, Ruan DT, Lee JA, Asa SL, Duh QY, Doherty GM, Herrera MF, Pasieka JL, Perrier ND, Silverberg SJ, Solorzano CC, Sturgeon C, Tublin ME, Udelsman R, Carty SE (2016) The American Association of Endocrine Surgeons Guidelines for definitive management of primary hyperparathyroidism. JAMA Surg 151(10):959–968. https://doi.org/10.1001/jamasurg.2016.2310 CrossRefPubMed

Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr (2014) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 99(10):3561–3569. https://doi.org/10.1210/jc.2014-1413 CrossRefPubMedPubMedCentral

10.

Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JE, Rejnmark L, Thakker R, D'Amour P, Paul T, Van Uum S, Shrayyef MZ, Goltzman D, Kaiser S, Cusano NE, Bouillon R, Mosekilde L, Kung AW, Rao SD, Bhadada SK, Clarke BL, Liu J, Duh Q, Lewiecki EM, Bandeira F, Eastell R, Marcocci C, Silverberg SJ, Udelsman R, Davison KS, Potts JT Jr, Brandi ML, Bilezikian JP (2017) Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int 28(1):1–19. https://doi.org/10.1007/s00198-016-3716-2 CrossRefPubMed

11.

Koumakis E, Souberbielle JC, Sarfati E, Meunier M, Maury E, Gallimard E, Borderie D, Kahan A, Cormier C (2013) Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab 98(8):3213–3220. https://doi.org/10.1210/jc.2013-1518 CrossRefPubMed

12.

Wade TJ, Yen TW, Amin AL, Wang TS (2012) Surgical management of normocalcemic primary hyperparathyroidism. World J Surg 36(4):761–766. https://doi.org/10.1007/s00268-012-1438-y CrossRefPubMed

13.

Amaral LM, Queiroz DC, Marques TF, Mendes M, Bandeira F (2012) Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone? J Osteoporos 2012:128352–128354. https://doi.org/10.1155/2012/128352 PubMedPubMedCentralCrossRef

14.

Lombardi CP, Raffaelli M, Traini E, De Crea C, Corsello SM, Bellantone R (2009) Video-assisted minimally invasive parathyroidectomy: benefits and long-term results. World J Surg 33(11):2266–2281. https://doi.org/10.1007/s00268-009-9931-7 CrossRefPubMed

15.

Lombardi CP, Raffaelli M, Traini E, Di Stasio E, Carrozza C, De Crea C, Zuppi C, Bellantone R (2008) Intraoperative PTH monitoring during parathyroidectomy: the need for stricter criteria to detect multiglandular disease. Langenbeck's Arch Surg 393(5):639–645. https://doi.org/10.1007/s00423-008-0384-5 CrossRef

16.

Cusano NE, Maalouf NM, Wang PY, Zhang C, Cremers SC, Haney EM, Bauer DC, Orwoll ES, Bilezikian JP (2013) Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. J Clin Endocrinol Metab 98(7):2734–2741. https://doi.org/10.1210/jc.2013-1300 CrossRefPubMedPubMedCentral

17.

Garcia-Martin A, Reyes-Garcia R, Munoz-Torres M (2012) Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women. Endocrine 42(3):764–766. https://doi.org/10.1007/s12020-012-9694-z CrossRefPubMed

18.

Marques TF, Vasconcelos R, Diniz E, Rego D, Griz L, Bandeira F (2011) Normocalcemic primary hyperparathyroidism in clinical practice: an indolent condition or a silent threat? Arq Bras Endocrinol Metabol 55(5):314–317. https://doi.org/10.1590/S0004-27302011000500003 CrossRefPubMedPubMedCentral

19.

Vignali E, Cetani F, Chiavistelli S, Meola A, Saponaro F, Centoni R, Cianferotti L, Marcocci C (2015) Normocalcemic primary hyperparathyroidism: a survey in a small village of Southern Italy. Endocr Connect 4(3):172–178. https://doi.org/10.1530/EC-15-0030 CrossRefPubMedPubMedCentral

20.

Berger C, Langsetmo L, Hanley, D, Hadachi J, Kovacs C, Brown J, Josse R, Goltzman D (2011) Relative prevalence of normocalcemic and hypercalcemic hyperparathyroidism in a community-dwelling cohort. Paper presented at the 33rd Annual Meeting of the American Society of Bone and Mineral Research, San Diego, California

21.

Maruani G, Hertig A, Paillard M, Houillier P (2003) Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab 88(10):4641–4648. https://doi.org/10.1210/jc.2002-021404 CrossRefPubMed

22.

Chen G, Xue Y, Zhang Q, Xue T, Yao J, Huang H, Liang J, Li L, Lin W, Lin L, Shi L, Cai L, Wen J (2015) Is normocalcemic primary hyperparathyroidism harmful or harmless? J Clin Endocrinol Metab 100:2420–2424. https://doi.org/10.1210/jc.2014-4432 CrossRefPubMed

23.

Pawloska M, Cusano NE (2015) An overview of normocalcemic primary hyperparathyroidism. Diabetes Curr Opin Endocrinol Diabetes Obes 22(6):413–421. https://doi.org/10.1097/MED.0000000000000198 CrossRef

24.

Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(7):1911–1300. https://doi.org/10.1210/jc.2011-0385 CrossRefPubMed

25.

Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ (2007) Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 92(8):3001–3005. https://doi.org/10.1210/jc.2006-2802 CrossRefPubMed

26.

Rao DS, Wilson RJ, Kleerekoper M, Parfitt AM (1988) Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. J Clin Endocrinol Metab 67(6):1294–1298. https://doi.org/10.1210/jcem-67-6-1294 CrossRefPubMed

27.

De Crea C, Raffaelli M, Traini E, Giustozzi E, Oragano L, Bellantone R, Lombardi CP (2013) Is there a role for video-assisted parathyroidectomy in regions with high prevalence of goitre? Acta Otorhinolaryngol Ital 33(6):388–392PubMed

28.

de la Plaza LR, Ramia Ángel JM, Arteaga Peralta V, García Amador C, López Marcano AJ, Medina Velasco AA, González Sierra B, Manuel Vázquez A, Latorre Fragua RA (2017) Elevated parathyroid hormone levels after successful parathyroidectomy for primary hyperparathyroidism: a clinical review. Eur Arch Otorhinolaryngol. https://doi.org/10.1007/s00405-017-4836-9

29.

Rejnmark L, Vestergaard P, Mosekilde L (2011) Nephrolithiasis and renal calcifications in primary hyperparathyroidism. J Clin Endocrinol Metab 96(8):2377–2385. https://doi.org/10.1210/jc.2011-0569 CrossRefPubMed

30.

Suh JM, Cronan JJ, Monchik JM (2008) Primary hyperparathyroidism: is there an increased prevalence of renal stone disease? AJR Am J Roentgenol 191(3):908–911. https://doi.org/10.2214/AJR.07.3160 CrossRefPubMed

Title: Is parathyroidectomy safe and effective in patients with normocalcemic primary hyperparathyroidism?
Authors: Emanuela Traini
Rocco Bellantone
Serena Elisa Tempera
Salvatore Russo
Carmela De Crea
Celestino Pio Lombardi
Marco Raffaelli
Publication date: 01-05-2018
Publisher: Springer Berlin Heidelberg
Published in: Langenbeck's Archives of Surgery / Issue 3/2018
Print ISSN: 1435-2443
Electronic ISSN: 1435-2451
DOI: https://doi.org/10.1007/s00423-018-1659-0

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Is parathyroidectomy safe and effective in patients with normocalcemic primary hyperparathyroidism?

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2018

Computer tomographic assessment of postoperative peripancreatic collections after distal pancreatectomy

Modern work-up and extended resection in perihilar cholangiocarcinoma: the AMC experience

Transparenchymal glissonean approach: a novel surgical technique for advanced perihilar bile duct cancer

Incidence and management of arterial injuries during pancreatectomy

Parathyroid autotransplantation in thyroid surgery

Continuous monitoring of the recurrent laryngeal nerve